Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

Core Viewpoint - Erasca, Inc. has received a patent for ERAS-4001, a pan-KRAS inhibitor, providing intellectual property protection until at least 2043, which strengthens its position in the RAS-driven cancer market [1][2] Group 1: Intellectual Property and Pipeline - The newly issued U.S. patent enhances the ERAS-4001 program and supports the company's diversified intellectual property strategy in RAS-driven cancers [2] - The patent protection for ERAS-4001 extends through at least 2043, with additional patents pending, providing a robust long-term IP foundation [2] - Initial Phase 1 monotherapy data for ERAS-0015 is expected in the first half of 2026, while data for ERAS-4001 is anticipated in the second half of 2026 [1] Group 2: Product Details - ERAS-4001 is an oral, highly potent, and selective pan-KRAS inhibitor currently being evaluated in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors [3] - Preclinical studies show ERAS-4001 has favorable potency against KRAS G12X mutations and wildtype amplifications, with no activity against HRAS or NRAS wildtype proteins [3] - ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS-1 Phase 1 trial, demonstrating favorable safety and tolerability, with early data showing responses in multiple patients [4] Group 3: Company Overview - Erasca is a clinical-stage precision oncology company focused on developing therapies for RAS/MAPK pathway-driven cancers, co-founded by pioneers in precision oncology [5] - The company's mission is to "erase cancer" through novel therapies and combination regimens targeting the RAS/MAPK pathway [5]